Tag: NBTXR3
Nanobiotix announces that it has completed the dose escalation portion of the Phase 1 study evaluating NBTXR3
By Claude Leguilloux Published on 04/03/2024 at 7:22 a.m. (Boursier.com) — Nanobiotix a French biotechnology company in…
Nanobiotix: transfer of rights to NBTXR3 in Asia – 12/27/2023 at 09:53
(CercleFinance.com) – Nanobiotix announces that its partner LianBio has entered into an agreement to transfer to Janssen Pharmaceutica, a subsidiary of Johnson & Johnson, the exclusive rights to develop and…
Nanobiotix: entry into force of the license agreement for the commercialization of NBTXR3
(AOF) – Clinical Biotechnology Company Nanobiotix Announces Expiry of Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 Waiting Period for Global Licensing, Co-Development and Commercialization Agreement with Janssen Pharmaceutica NV (an…
Nanobiotix: entry into force of the license agreement for the commercialization of NBTXR3 – 08/16/2023 at 08:09
(AOF) – Clinical Biotechnology Company Nanobiotix Announces Expiry of Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 Waiting Period for Global Licensing, Co-Development and Commercialization Agreement with Janssen Pharmaceutica NV (an…
Nanobiotix: the title explodes after the long-awaited global licensing agreement with Janssen for NBTXR3
By Jean-Baptiste Andre Published on 07/10/2023 at 09:14modified 07/10/2023 at 3:35 p.m. (Boursier.com) — In huge volumes, Nanobiotix soared by nearly 50% to 6.99 euros at the…
Nanobiotix: license agreement with Janssen for NBTXR3 – 07/10/2023 at 09:20
(CercleFinance.com) – Nanobiotix announces the signing of a global licensing, co-development and marketing agreement with Janssen, a subsidiary of Johnson & Johnson, for NBTXR3, a product-candidate currently being evaluated for…
Nanobiotix soars after signing an agreement with Janssen on its NBTXR3 product – 07/10/2023 at 10:00
Laurent Levy, CEO of Nanobiotix. (Photo credits: Nanobiotix) (AOF) – Nanobiotix (+43.90% to 6.72 euros) posted the largest increase in the SRD market after announcing the signing of a global…
Nanobiotix: Discussions on NBTXR3, the title flies away
Read also (CercleFinance.com) – The title Nanobiotix soars this Friday on the Paris Stock Exchange following information that the company is in talks with a ‘world leader in the pharmaceutical…
Nanobiotix: randomization of the 1st patient in the USA in the pivotal global Phase 3 trial evaluating the radioenhancer NBTXR3 in head and neck cancer
By Jean-Baptiste André Published on 27/12/2022 at 08:41 Photo credit © Nanobiotix (Boursier.com)…
NANOBIOTIX ANNOUNCES RECOMMENDED DOSE DETERMINATION FOR PHASE 2 OF NBTXR3 IN THE TREATMENT OF PANCREATIC CANCER – 11/14/2022 at 22:20
• The data collected on the entire dose escalation part of study 2019-1001 – a Phase 1 study evaluating NBTXR3 in patients with locally advanced pancreatic adenocarcinoma – show that…
SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 37TH ANNUAL MEETING: NANOBIOTIX PRESENTS UPDATED PHASE 1 DATA ON COMBINATION OF NBTXR3 WITH ANTI-PD-1, WHICH MAY SUPPORT RADIOENHANCER’S IMMUNE SYSTEM-BOOSTING POTENTIAL – 10 /11/2022 at 08:30
These data will be discussed during the conference call presenting Nanobiotix’s third quarter results, at 8 a.m. EST / 2 p.m. CET. • Data from the entire dose escalation part…
NANOBIOTIX APPOINTS LEADING EXPERTS TO FORM ITS SCIENTIFIC ADVISORY BOARD FOR NBTXR3, ITS POTENTIAL FIRST-IN-CLASS RADIOENHANCER – 02/11/2022 at 21:30
This multidisciplinary Scientific Council includes twelve (12) American and European experts contributing their expertise to the development of the main product-candidate NBTXR3Paris, France ; Cambridge, Massachusetts (USA); November 2, 2022…